Blockbuster Drugs

The Rise and Decline of the Pharmaceutical Industry

Nonfiction, Health & Well Being, Medical, Medical Science, Pharmacology
Cover of the book Blockbuster Drugs by Jie Jack Li, Oxford University Press
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: Jie Jack Li ISBN: 9780199911929
Publisher: Oxford University Press Publication: December 2, 2013
Imprint: Oxford University Press Language: English
Author: Jie Jack Li
ISBN: 9780199911929
Publisher: Oxford University Press
Publication: December 2, 2013
Imprint: Oxford University Press
Language: English

For the world's largest prescription drug manufacturers, the last few years have been a harrowing time. Recently, Pfizer's Lipitor, GlaxoSmithKline's Advair, AstraZeneca's Seroquel, and Sanofi-Aventis and Bristol-Myers Squibb's Plavix all came off patent in the crucial U.S. market. This so-called "patent cliff" meant hundreds of billions of dollars in lost revenue and has pharmaceutical developers scrambling to create new drugs and litigating to extend current patent protections. Having spent most of his career in drug discovery in "big pharma," Dr. Li now delivers an insider's account of how the drug industry ascended to its plateau and explores the nature of the turmoil it faces in the coming years. He begins with a survey of the landscape before "blockbuster drugs," and proceeds to describe how those drugs were discovered and subsequently became integral to the business models of large pharmaceutical companies. For example, in early 1980s, Tagamet, the first "blockbuster drug," transformed a minor Philadelphia-based drug maker named SmithKline & French into the world's ninth-largest pharmaceutical company in terms of sales. The project that delivered Tagamet was nearly terminated several times because research efforts begun in 1964 produced no apparent results within the first eleven years. Similar stories accompany the discovery and development of now-ubiquitous prescription drugs, among them Claritin, Prilosec, Nexium, Plavix, and Ambien. These stories, and the facets of the pharmaceutical industry that they reveal, can teach us valuable lessons and reveal many crucial aspects about the future landscape of drug discovery. As always, Dr. Li writes in a readable style and intersperses fascinating stories of scientific discovery with engaging human drama.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

For the world's largest prescription drug manufacturers, the last few years have been a harrowing time. Recently, Pfizer's Lipitor, GlaxoSmithKline's Advair, AstraZeneca's Seroquel, and Sanofi-Aventis and Bristol-Myers Squibb's Plavix all came off patent in the crucial U.S. market. This so-called "patent cliff" meant hundreds of billions of dollars in lost revenue and has pharmaceutical developers scrambling to create new drugs and litigating to extend current patent protections. Having spent most of his career in drug discovery in "big pharma," Dr. Li now delivers an insider's account of how the drug industry ascended to its plateau and explores the nature of the turmoil it faces in the coming years. He begins with a survey of the landscape before "blockbuster drugs," and proceeds to describe how those drugs were discovered and subsequently became integral to the business models of large pharmaceutical companies. For example, in early 1980s, Tagamet, the first "blockbuster drug," transformed a minor Philadelphia-based drug maker named SmithKline & French into the world's ninth-largest pharmaceutical company in terms of sales. The project that delivered Tagamet was nearly terminated several times because research efforts begun in 1964 produced no apparent results within the first eleven years. Similar stories accompany the discovery and development of now-ubiquitous prescription drugs, among them Claritin, Prilosec, Nexium, Plavix, and Ambien. These stories, and the facets of the pharmaceutical industry that they reveal, can teach us valuable lessons and reveal many crucial aspects about the future landscape of drug discovery. As always, Dr. Li writes in a readable style and intersperses fascinating stories of scientific discovery with engaging human drama.

More books from Oxford University Press

Cover of the book From Natural Character to Moral Virtue in Aristotle by Jie Jack Li
Cover of the book France: Oxford Bibliographies Online Research Guide by Jie Jack Li
Cover of the book Spirits of Blood, Spirits of Breath by Jie Jack Li
Cover of the book Working At Play by Jie Jack Li
Cover of the book Flares of Memory by Jie Jack Li
Cover of the book Music in the Nineteenth Century : The Oxford History of Western Music by Jie Jack Li
Cover of the book Understanding Events by Jie Jack Li
Cover of the book Split Screen Nation by Jie Jack Li
Cover of the book The Scarlet Letter by Jie Jack Li
Cover of the book The Balkans in World History by Jie Jack Li
Cover of the book The Jungle Book Level 2 Oxford Bookworms Library by Jie Jack Li
Cover of the book Nicolas Poussin by Jie Jack Li
Cover of the book The Infested Mind: Why Humans Fear, Loathe, and Love Insects by Jie Jack Li
Cover of the book El Libertador:Writings of Simon Bolivar by Jie Jack Li
Cover of the book Re-Creating the Corporation by Jie Jack Li
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy